Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 24 | 2025 | 827 | 4.360 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2024 | 85 | 4.210 |
Why?
|
| T-Lymphocytes | 23 | 2025 | 1707 | 3.800 |
Why?
|
| Receptors, Antigen, T-Cell | 16 | 2024 | 482 | 3.750 |
Why?
|
| CD5 Antigens | 3 | 2024 | 36 | 1.530 |
Why?
|
| Graft vs Host Disease | 4 | 2025 | 542 | 1.330 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2025 | 394 | 1.040 |
Why?
|
| Antigens, Neoplasm | 6 | 2024 | 386 | 1.000 |
Why?
|
| Cytotoxicity, Immunologic | 6 | 2025 | 263 | 0.990 |
Why?
|
| Cell Engineering | 2 | 2023 | 21 | 0.900 |
Why?
|
| Lymphoma, T-Cell | 1 | 2024 | 64 | 0.860 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 4 | 2025 | 25 | 0.830 |
Why?
|
| Immunologic Memory | 4 | 2025 | 187 | 0.730 |
Why?
|
| Gammaretrovirus | 2 | 2020 | 5 | 0.710 |
Why?
|
| Lymphocyte Activation | 7 | 2020 | 691 | 0.670 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 294 | 0.670 |
Why?
|
| Leukemia | 1 | 2023 | 369 | 0.660 |
Why?
|
| Gene Expression | 4 | 2020 | 1560 | 0.650 |
Why?
|
| Genetic Vectors | 3 | 2020 | 940 | 0.640 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 63 | 0.630 |
Why?
|
| Antigens, CD7 | 2 | 2018 | 11 | 0.600 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2024 | 538 | 0.580 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 766 | 0.560 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 781 | 0.550 |
Why?
|
| Listeriosis | 2 | 2014 | 20 | 0.550 |
Why?
|
| Animals | 25 | 2025 | 34016 | 0.550 |
Why?
|
| Listeria monocytogenes | 2 | 2014 | 31 | 0.550 |
Why?
|
| Graft Rejection | 1 | 2020 | 590 | 0.530 |
Why?
|
| Mice | 20 | 2025 | 17570 | 0.520 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 1198 | 0.510 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2013 | 108 | 0.490 |
Why?
|
| Genomics | 1 | 2023 | 1500 | 0.480 |
Why?
|
| Cell Line, Tumor | 9 | 2025 | 3334 | 0.440 |
Why?
|
| Lymphoma | 1 | 2017 | 322 | 0.430 |
Why?
|
| Antigens, CD19 | 4 | 2024 | 178 | 0.430 |
Why?
|
| Signal Transduction | 5 | 2025 | 4489 | 0.430 |
Why?
|
| Tissue Donors | 1 | 2017 | 494 | 0.430 |
Why?
|
| Hematologic Neoplasms | 3 | 2022 | 284 | 0.430 |
Why?
|
| Cell Proliferation | 4 | 2020 | 2286 | 0.420 |
Why?
|
| Transduction, Genetic | 3 | 2020 | 290 | 0.400 |
Why?
|
| Humans | 35 | 2025 | 124780 | 0.390 |
Why?
|
| Apoptosis | 5 | 2024 | 1790 | 0.390 |
Why?
|
| Neoplasms | 3 | 2022 | 2789 | 0.390 |
Why?
|
| Immunological Synapses | 2 | 2025 | 26 | 0.380 |
Why?
|
| Cell Differentiation | 3 | 2020 | 1883 | 0.370 |
Why?
|
| Interleukin-15 | 3 | 2020 | 92 | 0.360 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2024 | 882 | 0.320 |
Why?
|
| Chronic Disease | 2 | 2024 | 1189 | 0.320 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 158 | 0.320 |
Why?
|
| Transgenes | 3 | 2020 | 334 | 0.310 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 2043 | 0.290 |
Why?
|
| Killer Cells, Natural | 3 | 2020 | 327 | 0.280 |
Why?
|
| Transcription Factors | 2 | 2014 | 2580 | 0.260 |
Why?
|
| CD28 Antigens | 3 | 2025 | 79 | 0.250 |
Why?
|
| Cell Line | 2 | 2020 | 2746 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 325 | 0.230 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 59 | 0.230 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 104 | 0.220 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 76 | 0.210 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 183 | 0.210 |
Why?
|
| Cellular Senescence | 1 | 2024 | 161 | 0.200 |
Why?
|
| Bone Marrow Diseases | 1 | 2022 | 41 | 0.200 |
Why?
|
| Dasatinib | 1 | 2022 | 40 | 0.200 |
Why?
|
| Immunophenotyping | 2 | 2020 | 330 | 0.190 |
Why?
|
| Macaca mulatta | 1 | 2023 | 491 | 0.190 |
Why?
|
| Blood Platelets | 1 | 2024 | 327 | 0.180 |
Why?
|
| Immunotherapy | 3 | 2024 | 673 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2021 | 213 | 0.170 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 676 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1140 | 0.160 |
Why?
|
| Glypicans | 1 | 2020 | 39 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2022 | 759 | 0.160 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 152 | 0.160 |
Why?
|
| Recurrence | 1 | 2023 | 1421 | 0.160 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 4344 | 0.160 |
Why?
|
| Interleukins | 1 | 2020 | 120 | 0.160 |
Why?
|
| Mice, Inbred NOD | 4 | 2020 | 285 | 0.160 |
Why?
|
| Genetic Engineering | 1 | 2020 | 160 | 0.160 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 280 | 0.150 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 219 | 0.150 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2017 | 8 | 0.140 |
Why?
|
| Gene Editing | 1 | 2020 | 187 | 0.140 |
Why?
|
| 4-1BB Ligand | 1 | 2017 | 11 | 0.140 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2017 | 16 | 0.140 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2017 | 30 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 681 | 0.140 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2017 | 64 | 0.140 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 253 | 0.140 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 71 | 0.140 |
Why?
|
| CD3 Complex | 1 | 2017 | 86 | 0.140 |
Why?
|
| Mice, Knockout | 3 | 2014 | 3715 | 0.140 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 254 | 0.130 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2016 | 20 | 0.130 |
Why?
|
| Gene Silencing | 1 | 2017 | 235 | 0.130 |
Why?
|
| Tumor Escape | 1 | 2016 | 61 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 196 | 0.130 |
Why?
|
| Cell Survival | 2 | 2017 | 806 | 0.120 |
Why?
|
| Transplantation Chimera | 1 | 2015 | 37 | 0.120 |
Why?
|
| Flow Cytometry | 2 | 2017 | 797 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 208 | 0.120 |
Why?
|
| Gene Expression Regulation | 3 | 2014 | 2520 | 0.120 |
Why?
|
| Adoptive Transfer | 2 | 2013 | 236 | 0.120 |
Why?
|
| Seizures | 1 | 2020 | 874 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2020 | 3038 | 0.110 |
Why?
|
| Mice, SCID | 3 | 2022 | 568 | 0.110 |
Why?
|
| Receptor, Notch1 | 1 | 2014 | 64 | 0.110 |
Why?
|
| Ovalbumin | 1 | 2014 | 318 | 0.110 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 307 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 514 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2016 | 329 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 931 | 0.090 |
Why?
|
| Biomarkers | 1 | 2020 | 3066 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 2384 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 1313 | 0.080 |
Why?
|
| Homeostasis | 1 | 2013 | 679 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 469 | 0.070 |
Why?
|
| Myeloid Cells | 2 | 2018 | 101 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1211 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 4366 | 0.070 |
Why?
|
| Female | 5 | 2025 | 66592 | 0.070 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 374 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2010 | 1022 | 0.060 |
Why?
|
| Cytokines | 2 | 2022 | 1290 | 0.060 |
Why?
|
| Male | 3 | 2017 | 61298 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2021 | 8 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 149 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2022 | 324 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 353 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 419 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2020 | 176 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2021 | 662 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 536 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 1062 | 0.040 |
Why?
|
| fas Receptor | 1 | 2017 | 41 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 736 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 58 | 0.030 |
Why?
|
| Lentivirus | 1 | 2017 | 82 | 0.030 |
Why?
|
| Interleukin-7 | 1 | 2017 | 44 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2017 | 90 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 472 | 0.030 |
Why?
|
| Cell Death | 1 | 2017 | 240 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2017 | 227 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 468 | 0.030 |
Why?
|
| Child | 3 | 2022 | 24407 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2016 | 97 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2016 | 128 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 241 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1237 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 455 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5160 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 1735 | 0.020 |
Why?
|
| Pediatrics | 1 | 2021 | 1166 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 19317 | 0.020 |
Why?
|
| Blood Cells | 1 | 2010 | 49 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 5824 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2010 | 77 | 0.020 |
Why?
|
| Spleen | 1 | 2010 | 279 | 0.020 |
Why?
|
| Adult | 2 | 2022 | 29510 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 621 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2010 | 348 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 251 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 555 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1662 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 610 | 0.020 |
Why?
|
| United States | 1 | 2021 | 10898 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6550 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2704 | 0.020 |
Why?
|
| Cell Movement | 1 | 2009 | 836 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 3877 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 16330 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2812 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 9033 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12368 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 19771 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 26812 | 0.010 |
Why?
|